National Cancer Institute; Notice of Closed Meeting

• Published date: 15 July 2021
• Citation: 86 FR 37337
• Record Number: 2021-15073
• Section: Notices
• Court: National Institutes Of Health

Federal Register, Volume 86 Issue 133 (Thursday, July 15, 2021)

[Federal Register Volume 86, Number 133 (Thursday, July 15, 2021)]
                [Notices]
                [Pages 37337-37338]
                From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
                [FR Doc No: 2021-15073]
                -----------------------------------------------------------------------
                DEPARTMENT OF HEALTH AND HUMAN SERVICES
                National Institutes of Health
                National Cancer Institute; Notice of Closed Meeting
                 Pursuant to section 10(d) of the Federal Advisory Committee Act, as
                amended, notice is hereby given of the following meeting.
                 The meetings will be closed to the public in accordance with the
                provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
                U.S.C., as amended. The purpose of this meeting is to evaluate requests
                for preclinical development resources for potential new therapeutics
                for the
                [[Page 37338]]
                treatment of cancer. The outcome of the evaluation will provide
                information to internal NCI committees that will decide whether NCI
                should support requests and make available contract resources for
                development of the potential therapeutic to improve the treatment of
                various forms of cancer. The research proposals and the discussions
                could disclose confidential trade secrets or commercial property such
                as patentable material, and personal information concerning individuals
                associated with the proposed research projects, the disclosure of which
                would constitute a clearly unwarranted invasion of personal privacy.
                 Name of Committee: National Cancer Institute Special Emphasis
                Panel; JUN2021 Cycle 38 NExT SEP Committee Meeting.
                 Date: August 4, 2021.
                 Time: 9:00 a.m. to 3:00 p.m.
                 Agenda: To evaluate the NCI Experimental Therapeutics Program
                Portfolio.
                 Place: National Institutes of Health, 9000 Rockville Pike,
                Building 31, Room 3A44, Bethesda, Maryland 20892 (WebEx Meeting).
                 Contact Persons: Barbara Mroczkowski, Ph.D., Executive
                Secretary, Discovery Experimental Therapeutics Program, National
                Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD
                20817, (301) 496-4291, [email protected].
                 Toby Hecht, Ph.D., Executive Secretary, Development Experimental
                Therapeutics Program, National Cancer Institute, NIH, 9609 Medical
                Center Drive, Room 3W110, Rockville, MD 20850, (240) 276-5683,
                [email protected].
                (Catalogue of Federal Domestic Assistance Program Nos. 93.392,
                Cancer Construction; 93.393, Cancer Cause and Prevention Research;
                93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
                Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
                Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
                Control, National Institutes of Health, HHS)
                 Dated: July 12, 2021.
                Melanie J. Pantoja,
                Program Analyst, Office of Federal Advisory Committee Policy.
                [FR Doc. 2021-15073 Filed 7-14-21; 8:45 am]
                BILLING CODE 4140-01-P